Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.18 USD | +0.32% | +1.60% | -17.19% |
04/04 | Acumen Pharmaceuticals Signs Deal With Lonza to Manufacture Alzheimer's Treatment Drug | MT |
04/04 | Lonza Enters Manufacturing Agreement for Acumen’s Alzheimer’s Disease Drug Candidate | MT |
Business Summary
Number of employees: 52
Managers
Managers | Title | Age | Since |
---|---|---|---|
Daniel O'Connell
CEO | Chief Executive Officer | 54 | 01/06/01 |
Jim Doherty
PSD | President | 56 | 01/02 |
Matthew Zuga
DFI | Director of Finance/CFO | 58 | 01/21/01 |
Kasey Spencer
CTO | Chief Tech/Sci/R&D Officer | - | - |
Russell Barton
COO | Chief Operating Officer | 66 | 01/19/01 |
Eric Siemers
CTO | Chief Tech/Sci/R&D Officer | 68 | 01/18/01 |
Alexandria Braun
IRC | Investor Relations Contact | - | 01/22/01 |
Kathleen Pierce
PRN | Corporate Officer/Principal | - | - |
Amber Dilley
PRN | Corporate Officer/Principal | - | 01/21/01 |
Jasna Jerecic
PRN | Corporate Officer/Principal | - | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Daniel O'Connell
CEO | Chief Executive Officer | 54 | 01/06/01 |
Director/Board Member | 55 | 01/22/01 | |
Jeffrey Ives
BRD | Director/Board Member | 73 | 01/14/01 |
Sean Stalfort
BRD | Director/Board Member | 54 | 01/18/01 |
Derrell Porter
BRD | Director/Board Member | 53 | 04/23/04 |
Laura Stoppel
BRD | Director/Board Member | 38 | 01/20/01 |
Nathan Fountain
BRD | Director/Board Member | 61 | 01/21/01 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 60,079,778 | 54,596,907 ( 90.87 %) | 0 | 90.87 % |
Company contact information
Sector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-17.19% | 191M | |
+1.77% | 42.86B | |
+47.70% | 41.36B | |
+12.24% | 42.74B | |
-8.83% | 27.68B | |
+7.44% | 25.15B | |
-23.01% | 18.63B | |
+30.56% | 12.37B | |
-1.82% | 11.92B | |
+8.35% | 11.21B |
- Stock Market
- Equities
- ABOS Stock
- Company Acumen Pharmaceuticals, Inc.